Noel Ha

Dr. Noel Ha

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2017 in Micromachines
Verified
Journal Article
Open access
PDF file
NHNoel Ha
Noel Ha
SSSaman Sadeghi
Saman Sadeghi
RDR. Michael Van Dam
R. Michael Van Dam
Radiopharmaceuticals labeled with short-lived positron-emitting or gamma-emitting isotopes are injected into patients just prior to performing positron emission tomography (PET) or single photon emission tomography (SPECT) scans, respectively. These imaging modalities are widely used in clinical care, as well as in the development and evaluation of new therapies in clinical research. Prior to injection, these radiopharmaceuticals (tracers) must undergo quality control (QC) testing to ensure product purity, identity, and safety for human use. Quality tests can be broadly categorized as (i) pharmaceutical tests, needed to ensure molecular identity, physiological compatibility and that no microbiological, pyrogenic, chemical, or particulate contamination is present in the final preparation; and (ii) radioactive tests, needed to ensure proper dosing and that there are no radiochemical and radionuclidic impurities that could interfere with the biodistribution or imaging. Performing the required QC tests is cumbersome and time-consuming, and requires an array of expensive analytical chemistry equipment and significant dedicated lab space. Calibrations, day of use tests, and documentation create an additional burden. Furthermore, in contrast to ordinary pharmaceuticals, each batch of short-lived radiopharmaceuticals must be manufactured and tested within a short period of time to avoid significant losses due to radioactive decay. To meet these challenges, several efforts are underway to develop integrated QC testing instruments that automatically perform and document all of the required tests. More recently, microfluidic quality control systems have been gaining increasing attention due to vastly reduced sample and reagent consumption, shorter analysis times, higher detection sensitivity, increased multiplexing, and reduced instrumentation size. In this review, we describe each of the required QC tests and conventional testing methods, followed by a discussion of efforts to directly miniaturize the test or examples in the literature that could be implemented for miniaturized QC testing.

20 July 2021 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
NHNoel Ha
Noel Ha
MRMarkus de Raad
Markus de Raad
LHLa Zhen Han
La Zhen Han
AGAmber Golini
Amber Golini
CPChristopher J. Petzold
Christopher J. Petzold
TNTrent Northen
Trent Northen
The integration of mass spectrometry with microfluidics has the potential to create high-throughput, sensitivity, and specificity assays.

10 October 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JCJeffrey Collins
Jeffrey Collins
CWChristopher M. Waldmann
Christopher M. Waldmann
CDChristopher Drake
Christopher Drake
RSRoger Slavik
Roger Slavik
NHNoel Ha
Noel Ha
RDR. Michael Van Dam
R. Michael Van Dam
Significance: Molecular imaging with PET can provide a dynamic, whole-body picture of the rate of biological processes or distribution of biological targets by tracking the distribution of radiolabeled molecules or particles in the body over time. Continual efforts to develop new PET probes are expanding the variety of processes and targets that can be visualized, facilitating basic research, drug development, and patient care. However, access to these probes at all stages of their development is hindered by high costs arising, in large part, from the significant resources that are typically dedicated to production of a single probe. Emerging technologies with increased synthesis flexibility are allowing increased probe diversity with fewer resources and could significantly increase access to new molecular imaging agents.

7 May 2026 in Science
Verified
Journal Article
Closed access
AKArtis Klapars
Artis Klapars
AFAnna Fryszkowska
Anna Fryszkowska
SGStephanie Galanie
Stephanie Galanie
OAOmer Ad
Omer Ad
EAEllen Y. Aguilera
Ellen Y. Aguilera
WZWendy Zhong
Wendy Zhong
Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.

22 February 2018 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
JLJimmy Ly
Jimmy Ly
NHNoel Ha
Noel Ha
SCShilin Cheung
Shilin Cheung
RDR. Michael Van Dam
R. Michael Van Dam

1 September 2017 in Analytica Chimica Acta
Verified
Journal Article
Closed access
NHNoel Ha
Noel Ha
JLJimmy Ly
Jimmy Ly
JJJason Jones
Jason Jones
SCShilin Cheung
Shilin Cheung
RDR. Michael Van Dam
R. Michael Van Dam